Text and Data Mining valid from 2018-10-19
Received: 17 May 2018
Accepted: 9 October 2018
First Online: 19 October 2018
: Disclosures provided by the authors are available with this article at jco.org.The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to ExternalRef removed or ExternalRef removed.Apostolia M. TsimberidouConsulting or Advisory Role: RocheResearch Funding: EMD Serono (Inst), Baxter (Inst), Foundation Medicine (Inst), Onyx Pharmaceuticals (Inst), Bayer HealthCare Pharmaceuticals (Inst), Boston Biomedical (Inst), Placon Therapeutics (Inst), Immatics Biotechnologies (Inst), Karus Therapeutics (Inst), Tvardi Therapeutics (Inst), OBI Pharma (Inst)Laura A. LevitNo relationship to discloseRichard L. SchilskyResearch Funding:AstraZeneca (Inst), Bayer AG (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Eli Lilly (Inst), Merck (Inst), Pfizer (Inst)Steven D. AverbuchEmployment: Bristol-Myers SquibbStock and Other Ownership Interests: Bristol-Myers Squibb, Foundation MedicineDaniel ChenNo relationship to discloseJohn M. KirkwoodConsulting or Advisory Role: Bristol-Myers Squibb, Novartis, Array BioPharma, Merck, Roche, Amgen, ImmunocoreResearch Funding: Merck (Inst), Prometheus Laboratories (Inst)Lisa M. McShaneNo relationship to discloseElad Sharon No relationship to discloseKathryn F. MilehamConsulting or Advisory Role: AstraZenecaSpeakers’ Bureau: MerckResearch Funding: CelgeneMichael A. PostowHonoraria: Bristol-Myers Squibb, MerckConsulting or Advisory Role: Bristol-Myers Squibb, Novartis, Array BioPharma, NewLink Genetics, Incyte, MerckResearch Funding: Bristol-Myers Squibb (Inst), Novartis (Inst), Array BioPharma (Inst), Infinity Pharmaceuticals (Inst), Rgenix (Inst)
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.